FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2765967596> ?p ?o ?g. }

• W2765967596 endingPage "261" @default.
• W2765967596 startingPage "253" @default.
• W2765967596 abstract "To assess the efficacy and safety of once-weekly omarigliptin as monotherapy in people with type 2 diabetes mellitus (T2DM).People with T2DM not on glucose-lowering medications, or who were washed off monotherapy or low-dose dual therapy, were randomized double-blind to omarigliptin 25 mg (n=165) or matching omarigliptin placebo (n=164) for 24 weeks, followed by a 30-week period to assess continuing efficacy and safety longer-term of omarigliptin during which metformin was added to the placebo group and metformin placebo to the omarigliptin group.From a mean baseline HbA1c of 8.0-8.1%, the least squares mean (95% CI) change from baseline in HbA1c at week 24 (primary endpoint) was -0.49% (-0.73, -0.24) in the omarigliptin group and -0.10% (-0.34, 0.14) in the placebo group, for a between-group difference of -0.39% (-0.59, -0.19) (p<.001). Protocol deviation in use of metformin by 38 of 252 (15%) people whose samples were available for evaluation probably attenuated glycemic efficacy results, as suggested by the LS mean difference -0.53% (-0.75, -0.32) after censoring of such participants. At 24 and 54 weeks, the incidences of adverse events (AEs) were similar in the omarigliptin and placebo groups. During 54 weeks there were no AEs of symptomatic hypoglycemia in the omarigliptin group and 5 AEs in the placebo group. Over 54 weeks, a majority of the omarigliptin treatment had a persistent reduction in HbA1c, remaining rescue-free.In people with T2DM, omarigliptin monotherapy improved glycemic control over 54 weeks and was generally well tolerated with a low risk of hypoglycemia. ClinicalTrials.gov Identifier: NCT01717313. EudraCT Number: 2012-003626-24." @default.
• W2765967596 created "2017-11-10" @default.
• W2765967596 creator A5026935251 @default.
• W2765967596 creator A5027357772 @default.
• W2765967596 creator A5031396574 @default.
• W2765967596 creator A5031476174 @default.
• W2765967596 creator A5048221931 @default.
• W2765967596 creator A5049530400 @default.
• W2765967596 creator A5050417026 @default.
• W2765967596 creator A5064493392 @default.
• W2765967596 creator A5066865652 @default.
• W2765967596 creator A5078590370 @default.
• W2765967596 creator A5087844534 @default.
• W2765967596 date "2018-04-01" @default.
• W2765967596 modified "2023-10-16" @default.
• W2765967596 title "A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes" @default.
• W2765967596 cites W1769745813 @default.
• W2765967596 cites W1970125713 @default.
• W2765967596 cites W1977619586 @default.
• W2765967596 cites W2009999012 @default.
• W2765967596 cites W2033331104 @default.
• W2765967596 cites W2051462052 @default.
• W2765967596 cites W2074142099 @default.
• W2765967596 cites W2085862152 @default.
• W2765967596 cites W2106154942 @default.
• W2765967596 cites W2140480989 @default.
• W2765967596 cites W2151185776 @default.
• W2765967596 cites W2156150085 @default.
• W2765967596 cites W2574678721 @default.
• W2765967596 cites W2755409646 @default.
• W2765967596 doi "https://doi.org/10.1016/j.diabres.2017.10.018" @default.
• W2765967596 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/29079379" @default.
• W2765967596 hasPublicationYear "2018" @default.
• W2765967596 type Work @default.
• W2765967596 sameAs 2765967596 @default.
• W2765967596 citedByCount "11" @default.
• W2765967596 countsByYear W27659675962017 @default.
• W2765967596 countsByYear W27659675962018 @default.
• W2765967596 countsByYear W27659675962019 @default.
• W2765967596 countsByYear W27659675962020 @default.
• W2765967596 countsByYear W27659675962021 @default.
• W2765967596 countsByYear W27659675962023 @default.
• W2765967596 crossrefType "journal-article" @default.
• W2765967596 hasAuthorship W2765967596A5026935251 @default.
• W2765967596 hasAuthorship W2765967596A5027357772 @default.
• W2765967596 hasAuthorship W2765967596A5031396574 @default.
• W2765967596 hasAuthorship W2765967596A5031476174 @default.
• W2765967596 hasAuthorship W2765967596A5048221931 @default.
• W2765967596 hasAuthorship W2765967596A5049530400 @default.
• W2765967596 hasAuthorship W2765967596A5050417026 @default.
• W2765967596 hasAuthorship W2765967596A5064493392 @default.
• W2765967596 hasAuthorship W2765967596A5066865652 @default.
• W2765967596 hasAuthorship W2765967596A5078590370 @default.
• W2765967596 hasAuthorship W2765967596A5087844534 @default.
• W2765967596 hasBestOaLocation W27659675961 @default.
• W2765967596 hasConcept C126322002 @default.
• W2765967596 hasConcept C134018914 @default.
• W2765967596 hasConcept C142724271 @default.
• W2765967596 hasConcept C168563851 @default.
• W2765967596 hasConcept C197934379 @default.
• W2765967596 hasConcept C203092338 @default.
• W2765967596 hasConcept C204787440 @default.
• W2765967596 hasConcept C27081682 @default.
• W2765967596 hasConcept C2777180221 @default.
• W2765967596 hasConcept C2778763485 @default.
• W2765967596 hasConcept C2779306644 @default.
• W2765967596 hasConcept C2780323712 @default.
• W2765967596 hasConcept C2780473172 @default.
• W2765967596 hasConcept C2780668416 @default.
• W2765967596 hasConcept C2910068830 @default.
• W2765967596 hasConcept C555293320 @default.
• W2765967596 hasConcept C71924100 @default.
• W2765967596 hasConceptScore W2765967596C126322002 @default.
• W2765967596 hasConceptScore W2765967596C134018914 @default.
• W2765967596 hasConceptScore W2765967596C142724271 @default.
• W2765967596 hasConceptScore W2765967596C168563851 @default.
• W2765967596 hasConceptScore W2765967596C197934379 @default.
• W2765967596 hasConceptScore W2765967596C203092338 @default.
• W2765967596 hasConceptScore W2765967596C204787440 @default.
• W2765967596 hasConceptScore W2765967596C27081682 @default.
• W2765967596 hasConceptScore W2765967596C2777180221 @default.
• W2765967596 hasConceptScore W2765967596C2778763485 @default.
• W2765967596 hasConceptScore W2765967596C2779306644 @default.
• W2765967596 hasConceptScore W2765967596C2780323712 @default.
• W2765967596 hasConceptScore W2765967596C2780473172 @default.
• W2765967596 hasConceptScore W2765967596C2780668416 @default.
• W2765967596 hasConceptScore W2765967596C2910068830 @default.
• W2765967596 hasConceptScore W2765967596C555293320 @default.
• W2765967596 hasConceptScore W2765967596C71924100 @default.
• W2765967596 hasLocation W27659675961 @default.
• W2765967596 hasLocation W27659675962 @default.
• W2765967596 hasLocation W27659675963 @default.
• W2765967596 hasOpenAccess W2765967596 @default.
• W2765967596 hasPrimaryLocation W27659675961 @default.
• W2765967596 hasRelatedWork W1977389382 @default.
• W2765967596 hasRelatedWork W1991565451 @default.
• W2765967596 hasRelatedWork W2033851814 @default.
• W2765967596 hasRelatedWork W2072873519 @default.

• next